Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial

BACKGROUND AND AIMS: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present primary completion analysis from RIVETING, an ongoing, double-blind, randomised, parallel-group trial evaluating efficacy and safety of tofacitinib dose reduction to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Crohns Colitis
Autors principals: Vermeire, Séverine, Su, Chinyu, Lawendy, Nervin, Kobayashi, Taku, Sandborn, William J, Rubin, David T, Modesto, Irene, Gardiner, Sean, Kulisek, Nicole, Zhang, Haiying, Wang, Wenjin, Panés, Julian
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8256630/
https://ncbi.nlm.nih.gov/pubmed/33290538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjaa249
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars